138 related articles for article (PubMed ID: 34858829)
1. Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction.
Tian Y; Wang J; Qiao X; Zhang J; Li Y; Fan L; Zhang Z; Zhao X; Tan B; Wang D; Yang P; Zhao Q
Front Oncol; 2021; 11():756440. PubMed ID: 34858829
[TBL] [Abstract][Full Text] [Related]
2. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
3. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
[TBL] [Abstract][Full Text] [Related]
4. [Clinical implications of Naples prognostic scores in patients with resectable Siewert type II-III adenocarcinoma of the esophagogastric junction].
Jin P; Ma G; Liu Y; Ke B; Liu HM; Liang H; Zhang RP
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jan; 27(1):54-62. PubMed ID: 38262901
[No Abstract] [Full Text] [Related]
5. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
6. Effects of Preoperative Enteral Nutrition on Postoperative Recent Nutritional Status in Patients with Siewert II and III Adenocarcinoma of Esophagogastric Junction after Neoadjuvant Chemoradiotherapy.
Zhao Q; Li Y; Yu B; Yang P; Fan L; Tan B; Tian Y
Nutr Cancer; 2018; 70(6):895-903. PubMed ID: 30273016
[TBL] [Abstract][Full Text] [Related]
7. Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction.
Ge X; Zhao Q; Song Y; Li J; Liu M; Bai W; Qiao X
Eur J Surg Oncol; 2018 Apr; 44(4):502-508. PubMed ID: 29395438
[TBL] [Abstract][Full Text] [Related]
8. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
Zhao Q; Li Y; Wang J; Zhang J; Qiao X; Tan B; Tian Y; Shi G; Xu Q; Li R; Liu Y; Yang P
Am J Med Sci; 2015 Jun; 349(6):472-6. PubMed ID: 25996101
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of neoadjuvant chemoradiotherapy plus apatinib for patients with locally advanced, HER2-negative, Siewert's type II-III adenocarcinoma of esophagogastric junction: a single-arm, open-label, phase II trial.
Guo H; Li Y; Lin C; Cheng Y; Zhang Z; Wang D; Zhao X; Liu Y; Jing S; Yang P; Tian Y; Liu Y; Wang J; Zhao Q
Am J Transl Res; 2021; 13(8):9015-9023. PubMed ID: 34540013
[TBL] [Abstract][Full Text] [Related]
10. Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study.
Du R; Ming J; Geng J; Zhu X; Zhang Y; Li S; Liu Z; Wang H; Wang Z; Tang L; Zhang X; Wu A; Bu Z; Yan Y; Li Z; Li Y; Li Z; Wang W
Radiat Oncol; 2022 Mar; 17(1):45. PubMed ID: 35241109
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
12. The abdominal-transhiatal surgical approach versus the thoracoabdominal surgical approach in Siewert type II adenocarcinoma of the esophagogastric junction: protocol for a multicenter prospective, open, parallel, and randomized controlled trial.
Song Q; Li X; Wu D; Li S; Xie T; Lu Y; Zhang L; Xu Z; Liu L; Guo X; Wang X
BMC Cancer; 2022 Mar; 22(1):318. PubMed ID: 35331180
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of sarcopenia in patients with locally advanced adenocarcinoma of the esophagogastric junction treated with neoadjuvant chemoradiotherapy.
Ming J; Du R; Geng J; Li S; Liu Z; Cai Y; Zhu X; Zhang Y; Wang H; Wang Z; Tang L; Zhang X; Peng Z; Wu A; Bu Z; Peng Y; Yan Y; Li Z; Li Y; Li Z; Wang W
Front Nutr; 2023; 10():988632. PubMed ID: 36776611
[TBL] [Abstract][Full Text] [Related]
14. Should Splenic Hilar Lymph Nodes be Dissected for Siewert Type II and III Esophagogastric Junction Carcinoma Based on Tumor Diameter?: A Retrospective Database Analysis.
Lv CB; Huang CM; Zheng CH; Li P; Xie JW; Wang JB; Lin JX; Lu J; Chen QY; Cao LL; Lin M; Tu RH
Medicine (Baltimore); 2016 May; 95(21):e3473. PubMed ID: 27227913
[TBL] [Abstract][Full Text] [Related]
15. Comparison of thoracoabdominal versus abdominal-transhiatal surgical approaches in Siewert type II adenocarcinoma at the esophagogastric junction: Protocol for a prospective multicenter randomized controlled trial.
Yue C; Mo Z; Wu X; Wang Y; Yang Q; Wang W; Zhou H; Gao R; Ji P; Dong D; Zhang Y; Ji G; Li X
Front Oncol; 2023; 13():1091615. PubMed ID: 37064105
[TBL] [Abstract][Full Text] [Related]
16. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes of neoadjuvant and adjuvant chemoradiotherapy for locally advanced adenocarcinoma of the oesophagogastric junction: a retrospective cohort study using the SEER database.
Zhang F; Feng X; Li Y; Yan J; Zhang Z; Song X
J Gastrointest Oncol; 2022 Feb; 13(1):26-39. PubMed ID: 35284136
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
[TBL] [Abstract][Full Text] [Related]
20. Long-term oncological outcomes of laparoscopic versus open transhiatal resection for patients with Siewert type II adenocarcinoma of the esophagogastric junction.
Sugita S; Kinoshita T; Kuwata T; Tokunaga M; Kaito A; Watanabe M; Tonouchi A; Sato R; Nagino M
Surg Endosc; 2021 Jan; 35(1):340-348. PubMed ID: 32025923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
